<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02088073</url>
  </required_header>
  <id_info>
    <org_study_id>ZS-004</org_study_id>
    <nct_id>NCT02088073</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.</brief_title>
  <official_title>Multicenter, Multi-phase, Multi-dose, Prospective, Double-blind, Placebo-controlled, Maintenance Study of Safety and Efficacy of ZS (Microporous, Fractionated, Protonated Zirconium Silicate) in Hyperkalemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ZS Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ZS Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is hypothesized that ZS is more effective than placebo control (alternative hypothesis) in
      maintaining mean double-blind randomized maintenance phase (DBRMP) Day 8-29 serum potassium
      levels (3.5 - 5.0 mmol/l, inclusive) among hyperkalemic subjects in whom normokalemia was
      established during the open-label acute phase versus no difference between each ZS dose
      (highest to lowest) versus placebo control (null hypothesis).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 275 subjects with hyperkalemia (two consecutive i-STAT potassium levels ≥ 5.1
      mmol/l, taken 60 minutes apart at baseline) will be enrolled in the Open-label Acute Phase to
      provide 232 subjects in the Double Blind Randomized Maintenance Phase.

      Initially all subjects will receive open-label ZS at a dose of 10g three times a day (tid)
      for 48 hours (AP). Subjects who achieve normokalemia (i-STAT potassium values between 3.5 to
      5.0 mmol/l, inclusive) on the morning of Study Day 3 (after 6 doses of 10g ZS) will then, in
      a double-blind fashion, be randomized 4:4:4:7 to receive one of three doses of ZS (5g, 10g or
      15g) or placebo control, qd for the following 28 days (DBRMP).

      Safety and tolerability will be assessed on an ongoing basis by an Independent Data
      Monitoring Committee (iDMC). Each active dose group in the DBRMP will consist of 49 subjects
      and the placebo control group will consist of 85 subjects for a total of 232 subjects to
      detect a 0.6 effect size difference between each ZS dose (from highest to lowest) and placebo
      control; the 4:4:4:7 allocation optimizes the multiple comparisons to the placebo control for
      the DBRMP.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2014</start_date>
  <completion_date type="Actual">January 31, 2015</completion_date>
  <primary_completion_date type="Actual">August 31, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Serum Potassium Between Maintenance Phase Study Days 8 to 29, Inclusive (MP-ITT Population).</measure>
    <time_frame>22 Days; Maintenance Phase Days 8 - 29, inclusive.</time_frame>
    <description>The least squares means (LSMeans) are dervied from a mixed effects model of serial log transformed S-K values between Days 8 and 29 with patients as a random effect and the following fixed effects terms: MP treatment group; AP baseline eGFR; AP and MP baseline S-K levels, age categories (&lt;55, 55-64, &gt;= 65 years); and binary indicators for RAAS inhibitors use, CKD, CHF, and DM. The LSmeans estimate obtained from the above model is back-transformed and presented as the lsmeans of all available S-K values during the Maintenance phase study Days 8 to 29.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Normokalemic Days Between Maintenance Phase Study Days 8 to 29, Inclusive (MP-ITT).</measure>
    <time_frame>22 days; Maintenance Phase Day 8 - 29, inclusive.</time_frame>
    <description>The number of normokalemic days during the Maintenance Phase Study Days 8 to 29 is calculated assuming that the interval between assessments is normokalemic only if both the beginning and end assessments for that time interval display normal S-K values (i.e. 3.5 - 5.0 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in S-K Levels From Acute Phase Baseline to Maintenance Phase Study Day 2 to Day 29/Exit .</measure>
    <time_frame>Acute Phase baseline to Maintenance Phase Study Day 2 to Day 29/Exit, inclusive.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change in S-K Levels From Acute Phase Baseline to Maintenance Phase Study Day 2 to Day 29/Exit, Inclusive .</measure>
    <time_frame>Acute Phase baseline to Maintenance Phase Study Day 2 to Day 29/Exit, inclusive.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in S-K Levels From Maintenance Phase Baseline to Maintenance Phase Day 2 to Day 29/Exit.</measure>
    <time_frame>Maintenance phase baseline to Maintenance Phase Study Day 29/Exit, inclusive.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change in S-K Levels From Maintenance Phase Baseline to Maintenance Phase Day 2 to Day 29/Exit.</measure>
    <time_frame>Maintenance phase baseline to Maintenance Phase Study Day 29/Exit, inclusive.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Hyperkalemia (S-K ≥ 5.1mmol/L)</measure>
    <time_frame>Maintenance Phase baseline to maintenance Phase Study Day 29/Exit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean S-K Intra-subject Standard Deviation Calculated Among Subjects With ≥ 2 Values on or After Maintenance Phase Study Day 8</measure>
    <time_frame>22 days; Maintenance Phase Day 8 - 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Who Remained Normokalemic During Maintenance Phase</measure>
    <time_frame>Maintenance Phase Study Days 1, 2, 5, 8, 12, 15, 19, 22, 26, 29, and 35, inclusive.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Relapse in S-K Values</measure>
    <time_frame>Maintenance phase Study Day 1 to Study Day 29/Exit.</time_frame>
    <description>Median time to relapse in S-K values (return to original Acute Phase S-K baseline value)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exponential Rate of Change in S-K Values During the Acute Phase at 24 Hours and 48 Hours of Study Drug Treatment.</measure>
    <time_frame>Acute Phase 24 hours and Acute Phase 48 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in S-K Values (Blood) at All Measured Time Intervals Post Dose Acute Phase.</measure>
    <time_frame>All measured time intervals post dose during the Acute Phase.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline in S-K Values (Blood) at All Measured Time Intervals Post Dose Acute Phase.</measure>
    <time_frame>All measured time intervals post dose during the Acute Phase.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Who Achieve Normokalemia During the Acute Phase at 24 and 48 Hours After Start of Dosing</measure>
    <time_frame>Through 48 hours acute phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Normalization (3.50-5.0 mmol/L) in S-K Levels in the 48 Hours of Initial Treatment</measure>
    <time_frame>Through 48 hours acute phase</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">258</enrollment>
  <condition>Hyperkalemia</condition>
  <arm_group>
    <arm_group_label>Sodium zirconium cyclosilicate 10 g three times daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium zirconium cyclosilicate 10 g three times daily for 48 hours (acute phase)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo once daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium zirconium cyclosilicate 5 g once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium zirconium cyclosilicate (ZS) 5 g once daily for 28 days (maintenance phase)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium zirconium cyclosilicate 10 g once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium zirconium cyclosilicate (ZS) 10 g once daily for 28 days (maintenance phase)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium zirconium cyclosilicate 15 g once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium zirconium cyclosilicate (ZS) 15 g once daily for 28 days (maintenance phase)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium zirconium cyclosilicate</intervention_name>
    <description>Sodium zirconium cyclosilicate</description>
    <arm_group_label>Sodium zirconium cyclosilicate 10 g once daily</arm_group_label>
    <arm_group_label>Sodium zirconium cyclosilicate 10 g three times daily</arm_group_label>
    <arm_group_label>Sodium zirconium cyclosilicate 15 g once daily</arm_group_label>
    <arm_group_label>Sodium zirconium cyclosilicate 5 g once daily</arm_group_label>
    <other_name>ZS; Microporous, Fractionated, Protonated Zirconium Silicate; Zirconium Silicate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days (maintenance phase)</description>
    <arm_group_label>Placebo once daily</arm_group_label>
    <other_name>Silicilate microcrystaline cellulose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written informed consent.

          -  Over 18 years of age.

          -  Two consecutive i-STAT potassium values, measured 60-minutes apart, both ≥5.1 mmol/l
             and measured within 1 day of the first ZS dose on AP Study Day 1.

          -  Ability to have repeated blood draws or effective venous catheterization.

          -  Women of childbearing potential must be using two forms of medically acceptable
             contraception (at least one barrier method) and have a negative pregnancy test at AP
             Study Day 1. Women who are surgically sterile or those who are post-menopausal for at
             least 2 years are not considered to be of childbearing potential.

        Exclusion Criteria:

          -  Pseudohyperkalemia signs and symptoms, such as excessive fist clenching hemolyzed
             blood specimen, history of severe leukocytosis or thrombocytosis.

          -  Subjects treated with lactulose, Xifaxan or other non-absorbed antibiotics for
             hyperammonemia within 7 days prior to the first dose of study drug.

          -  Subjects treated with resins (such as sevelamer acetate or sodium polystyrene
             sulfonate [SPS; e.g. Kayexalate®]), calcium acetate, calcium carbonate, or lanthanum
             carbonate, within 7 days prior to the first dose of study drug.

          -  Subjects with a life expectancy of less than 3 months.

          -  Subjects who are severely physically or mentally incapacitated and who in the opinion
             of investigator are unable to perform the subjects' tasks associated with the
             protocol.

          -  Women who are pregnant, lactating, or planning to become pregnant.

          -  Subjects with diabetic ketoacidosis.

          -  Presence of any condition which, in the opinion of the investigator, places the
             subject at undue risk or potentially jeopardizes the quality of the data to be
             generated.

          -  Known hypersensitivity or previous anaphylaxis to ZS or to components thereof.

          -  Randomization into the previous ZS-002 or ZS-003 studies.

          -  Treatment with a drug or device within the last 30 days that has not received
             regulatory approval at the time of study entry.

          -  Subjects with cardiac arrhythmias that require immediate treatment.

          -  Subjects on dialysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Rasmussen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>ZS Pharma, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsboro</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hawaiian Gardens</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Smyrna Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Summerfield</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evergreen Park</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sumter</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meyerspark</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Somerset West</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>March 12, 2014</study_first_submitted>
  <study_first_submitted_qc>March 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2014</study_first_posted>
  <results_first_submitted>July 18, 2017</results_first_submitted>
  <results_first_submitted_qc>November 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 7, 2018</results_first_posted>
  <disposition_first_submitted>August 26, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>August 26, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 28, 2014</disposition_first_posted>
  <last_update_submitted>November 13, 2018</last_update_submitted>
  <last_update_submitted_qc>November 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkalemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 44 sites in the United States, Australia, and South Africa from 31 March 2014 to 08 August 2014</recruitment_details>
      <pre_assignment_details>Subjects with hyperkalemia (i-STAT potassium value ≥ 5.1 mmol/L) were enrolled in the Acute Phase (AP) and were to be treated with ZS 10 g TID for the 48 hours.Subjects who achieved normokalemia during the AP were randomized to 1 of 3 doses of ZS (5 g, 10 g,or 15 g) or placebo for a further 28 days (Maintenance Phase [MP]).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ZS 10 g Three Times Daily (Acute Phase)</title>
          <description>Sodium zirconium cyclosilicate (ZS) 10 g, three times daily (TID), orally as a suspension for 48 hours.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Comparator (Maintenance Phase)</title>
          <description>Placebo to mimic doses of experimental drug once daily between Days 8 to 29, inclusive.</description>
        </group>
        <group group_id="P3">
          <title>ZS 5 g Once Daily (Maintenance Phase)</title>
          <description>Sodium zirconium cyclosilicate (ZS) 5 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
        </group>
        <group group_id="P4">
          <title>ZS 10 g Once Daily (Maintenance Phase)</title>
          <description>Sodium zirconium cyclosilicate (ZS) 10 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
        </group>
        <group group_id="P5">
          <title>ZS 15 g Once Daily (Maintenance Phase)</title>
          <description>Sodium zirconium cyclosilicate (ZS) 15 g, once daily, orally as a suspension between Day 8 to 29, inclusive.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Acute Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="258"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="251"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hyperkalemia</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintanance Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">251 subjects completed the AP; 240 were eligible to enter the MP. 237 entered the MP.</participants>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="44"/>
                <participants group_id="P5" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor's decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hypo- or hyperkalemia</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met ECG withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Some participants contributed to more than one baseline group. 258 participants entered the acute phase; 251 completed the acute phase. Of these 251 participants, 240 were eligible for the maintenance phase. Three participants did not enter the maintenance phase; 237 participants were randomized for the maintenance phase.</population>
      <group_list>
        <group group_id="B1">
          <title>ZS 10 g Three Times Daily (Acute Phase)</title>
          <description>Sodium zirconium cyclosilicate (ZS) 10 g, three times daily (TID), orally as a suspension for 48 hours.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Comparator (Maintenance Phase)</title>
          <description>Placebo to mimic doses of experimental drug once daily between Days 8 to 29, inclusive.</description>
        </group>
        <group group_id="B3">
          <title>ZS 5 g Once Daily (Maintenance Phase)</title>
          <description>Sodium zirconium cyclosilicate (ZS) 5 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
        </group>
        <group group_id="B4">
          <title>ZS 10 g Once Daily (Maintenance Phase)</title>
          <description>Sodium zirconium cyclosilicate (ZS) 10 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
        </group>
        <group group_id="B5">
          <title>ZS 15 g Once Daily (Maintenance Phase)</title>
          <description>Sodium zirconium cyclosilicate (ZS) 15 g, once daily, orally as a suspension between Day 8 to 29, inclusive.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="258"/>
            <count group_id="B2" value="85"/>
            <count group_id="B3" value="45"/>
            <count group_id="B4" value="51"/>
            <count group_id="B5" value="56"/>
            <count group_id="B6" value="495"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Acute Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.0" spread="12.72"/>
                    <measurement group_id="B2" value="NA" spread="NA">This field does not apply to the Acute Phase of the study.</measurement>
                    <measurement group_id="B3" value="NA" spread="NA">This field does not apply to the Acute Phase of the study.</measurement>
                    <measurement group_id="B4" value="NA" spread="NA">This field does not apply to the Acute Phase of the study.</measurement>
                    <measurement group_id="B5" value="NA" spread="NA">This field does not apply to the Acute Phase of the study.</measurement>
                    <measurement group_id="B6" value="64.0" spread="12.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maintenance Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA" spread="NA">This field does not apply to the Maintenance Phase of the study.</measurement>
                    <measurement group_id="B2" value="64.3" spread="12.13"/>
                    <measurement group_id="B3" value="61.5" spread="16.89"/>
                    <measurement group_id="B4" value="63.8" spread="9.97"/>
                    <measurement group_id="B5" value="64.9" spread="12.85"/>
                    <measurement group_id="B6" value="63.80" spread="13.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female, Acute Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male, Acute Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female, Maintenance Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male, Maintenance Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="40"/>
                    <measurement group_id="B6" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White, Acute Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="215"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American, Acute Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian, Acute Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islander, AP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other, Acute Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Races indicated, Acute Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White, Maintenance Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="46"/>
                    <measurement group_id="B6" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American, Maintenance Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian, Maintenance Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islander, MP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other, Maintenance Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Races indicated, Maintenance Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Serum potassium ( S-K ) levels during both the Acute and Maintenance phases</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;5.5 mmol/L, Acute Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5.5-&lt;6.0 mmol/L, Acute Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 6.0 mmol/L, Acute Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;5.5 mmol/L, Maintenance Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5.5-&lt;6.0 mmol/L, Maintenance Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 6.0 mmol/L, Maintenance Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>eGFR at baseline during both the Acute and Maintenance phases</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;60 mL/min, Acute Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 60 mL/min, Acute Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not reported, Acute Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;60 mL/min, Maintenance Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 60 mL/min, Maintenance Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not reported, Maintenance Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Etiology of elevated S-K levels during both the Acute and Maintenance phases</title>
          <description>Categories not mutually exclusive</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>RAAS inhibitor medication, Acute Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes mellitus, Acute Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic kidney disease, Acute Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart failure, Acute Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RAAS inhibitor medication, Maintenance Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes mellitus, Maintenance Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic kidney disease, Maintenance Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart failure, Maintenance Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Serum Potassium Between Maintenance Phase Study Days 8 to 29, Inclusive (MP-ITT Population).</title>
        <description>The least squares means (LSMeans) are dervied from a mixed effects model of serial log transformed S-K values between Days 8 and 29 with patients as a random effect and the following fixed effects terms: MP treatment group; AP baseline eGFR; AP and MP baseline S-K levels, age categories (&lt;55, 55-64, &gt;= 65 years); and binary indicators for RAAS inhibitors use, CKD, CHF, and DM. The LSmeans estimate obtained from the above model is back-transformed and presented as the lsmeans of all available S-K values during the Maintenance phase study Days 8 to 29.</description>
        <time_frame>22 Days; Maintenance Phase Days 8 - 29, inclusive.</time_frame>
        <population>Maintenance Phase Intent- to-Treat (MP-ITT) population: all randomized patients who received at least 1 Maintenance Phase dose and had at least 1 observed S-K assessment on or after Study Day 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator (Maintenance Phase)</title>
            <description>Placebo to mimic doses of experimental drug once daily between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O2">
            <title>ZS 5 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 5 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O3">
            <title>ZS 10 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 10 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O4">
            <title>ZS 15 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 15 g, once daily, orally as a suspension between Day 8 to 29, inclusive.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum Potassium Between Maintenance Phase Study Days 8 to 29, Inclusive (MP-ITT Population).</title>
          <description>The least squares means (LSMeans) are dervied from a mixed effects model of serial log transformed S-K values between Days 8 and 29 with patients as a random effect and the following fixed effects terms: MP treatment group; AP baseline eGFR; AP and MP baseline S-K levels, age categories (&lt;55, 55-64, &gt;= 65 years); and binary indicators for RAAS inhibitors use, CKD, CHF, and DM. The LSmeans estimate obtained from the above model is back-transformed and presented as the lsmeans of all available S-K values during the Maintenance phase study Days 8 to 29.</description>
          <population>Maintenance Phase Intent- to-Treat (MP-ITT) population: all randomized patients who received at least 1 Maintenance Phase dose and had at least 1 observed S-K assessment on or after Study Day 8.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0603" lower_limit="4.9646" upper_limit="5.1578"/>
                    <measurement group_id="O2" value="4.7544" lower_limit="4.6350" upper_limit="4.8769"/>
                    <measurement group_id="O3" value="4.5081" lower_limit="4.4005" upper_limit="4.6184"/>
                    <measurement group_id="O4" value="4.3742" lower_limit="4.2754" upper_limit="4.4753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Normokalemic Days Between Maintenance Phase Study Days 8 to 29, Inclusive (MP-ITT).</title>
        <description>The number of normokalemic days during the Maintenance Phase Study Days 8 to 29 is calculated assuming that the interval between assessments is normokalemic only if both the beginning and end assessments for that time interval display normal S-K values (i.e. 3.5 - 5.0 mmol/L)</description>
        <time_frame>22 days; Maintenance Phase Day 8 - 29, inclusive.</time_frame>
        <population>Maintenance Phase Intent- to-Treat (MP-ITT) population: all randomized patients who received at least 1 Maintenance Phase dose and had at least 1 observed S-K assessment on or after Study Day 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator (Maintenance Phase)</title>
            <description>Placebo to mimic doses of experimental drug once daily between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O2">
            <title>ZS 5 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 5 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O3">
            <title>ZS 10 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 10 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O4">
            <title>ZS 15 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 15 g, once daily, orally as a suspension between Day 8 to 29, inclusive.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Normokalemic Days Between Maintenance Phase Study Days 8 to 29, Inclusive (MP-ITT).</title>
          <description>The number of normokalemic days during the Maintenance Phase Study Days 8 to 29 is calculated assuming that the interval between assessments is normokalemic only if both the beginning and end assessments for that time interval display normal S-K values (i.e. 3.5 - 5.0 mmol/L)</description>
          <population>Maintenance Phase Intent- to-Treat (MP-ITT) population: all randomized patients who received at least 1 Maintenance Phase dose and had at least 1 observed S-K assessment on or after Study Day 8.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="8.0"/>
                    <measurement group_id="O2" value="13.4" spread="7.57"/>
                    <measurement group_id="O3" value="13.9" spread="7.91"/>
                    <measurement group_id="O4" value="16.8" spread="6.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in S-K Levels From Acute Phase Baseline to Maintenance Phase Study Day 2 to Day 29/Exit .</title>
        <time_frame>Acute Phase baseline to Maintenance Phase Study Day 2 to Day 29/Exit, inclusive.</time_frame>
        <population>Maintenance Phase Intent- to-Treat (MP-ITT) population: all randomized subjects who received at least 1 Maintenance Phase dose and had at least 1 observed S-K assessment on or after Study Day 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator (Maintenance Phase)</title>
            <description>Placebo to mimic doses of experimental drug once daily between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O2">
            <title>ZS 5 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 5 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O3">
            <title>ZS 10 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 10 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O4">
            <title>ZS 15 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 15 g, once daily, orally as a suspension between Day 8 to 29, inclusive.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in S-K Levels From Acute Phase Baseline to Maintenance Phase Study Day 2 to Day 29/Exit .</title>
          <population>Maintenance Phase Intent- to-Treat (MP-ITT) population: all randomized subjects who received at least 1 Maintenance Phase dose and had at least 1 observed S-K assessment on or after Study Day 8.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AP Baseline S-K level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.55" spread="0.471"/>
                    <measurement group_id="O2" value="5.53" spread="0.357"/>
                    <measurement group_id="O3" value="5.58" spread="0.423"/>
                    <measurement group_id="O4" value="5.55" spread="0.331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 2 Mean Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="0.508"/>
                    <measurement group_id="O2" value="-1.03" spread="0.408"/>
                    <measurement group_id="O3" value="-1.25" spread="0.471"/>
                    <measurement group_id="O4" value="-1.12" spread="0.477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 8 Mean Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="0.549"/>
                    <measurement group_id="O2" value="-0.72" spread="0.552"/>
                    <measurement group_id="O3" value="-1.09" spread="0.629"/>
                    <measurement group_id="O4" value="-1.20" spread="0.592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 12 Mean Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.508"/>
                    <measurement group_id="O2" value="-0.75" spread="0.516"/>
                    <measurement group_id="O3" value="-1.11" spread="0.663"/>
                    <measurement group_id="O4" value="-1.20" spread="0.665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 15 Mean Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.612"/>
                    <measurement group_id="O2" value="-0.77" spread="0.492"/>
                    <measurement group_id="O3" value="-1.11" spread="0.652"/>
                    <measurement group_id="O4" value="-1.19" spread="0.627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 19 Mean Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.549"/>
                    <measurement group_id="O2" value="-0.79" spread="0.520"/>
                    <measurement group_id="O3" value="-1.04" spread="0.581"/>
                    <measurement group_id="O4" value="-1.07" spread="0.575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 22 Mean Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.578"/>
                    <measurement group_id="O2" value="-0.71" spread="0.543"/>
                    <measurement group_id="O3" value="-0.93" spread="0.653"/>
                    <measurement group_id="O4" value="-1.05" spread="0.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 26 Mean Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.552"/>
                    <measurement group_id="O2" value="-0.65" spread="0.448"/>
                    <measurement group_id="O3" value="-0.87" spread="0.697"/>
                    <measurement group_id="O4" value="-1.03" spread="0.597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 29 Mean Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.499"/>
                    <measurement group_id="O2" value="-0.69" spread="0.500"/>
                    <measurement group_id="O3" value="-1.08" spread="0.704"/>
                    <measurement group_id="O4" value="-1.12" spread="0.571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 29/Exit Mean Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.515"/>
                    <measurement group_id="O2" value="-0.77" spread="0.559"/>
                    <measurement group_id="O3" value="-1.10" spread="0.813"/>
                    <measurement group_id="O4" value="-1.19" spread="0.659"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change in S-K Levels From Acute Phase Baseline to Maintenance Phase Study Day 2 to Day 29/Exit, Inclusive .</title>
        <time_frame>Acute Phase baseline to Maintenance Phase Study Day 2 to Day 29/Exit, inclusive.</time_frame>
        <population>Maintenance Phase Intent- to-Treat (MP-ITT) population: all randomized subjects who received at least 1 Maintenance Phase dose and had at least 1 observed S-K assessment on or after Study Day 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator (Maintenance Phase)</title>
            <description>Placebo to mimic doses of experimental drug once daily between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O2">
            <title>ZS 5 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 5 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O3">
            <title>ZS 10 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 10 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O4">
            <title>ZS 15 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 15 g, once daily, orally as a suspension between Day 8 to 29, inclusive.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in S-K Levels From Acute Phase Baseline to Maintenance Phase Study Day 2 to Day 29/Exit, Inclusive .</title>
          <population>Maintenance Phase Intent- to-Treat (MP-ITT) population: all randomized subjects who received at least 1 Maintenance Phase dose and had at least 1 observed S-K assessment on or after Study Day 8.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MP Study Day 2 Percent Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.11" spread="8.154"/>
                    <measurement group_id="O2" value="-18.53" spread="6.941"/>
                    <measurement group_id="O3" value="-22.19" spread="7.897"/>
                    <measurement group_id="O4" value="-20.04" spread="7.959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 8 Percent Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.45" spread="9.492"/>
                    <measurement group_id="O2" value="-12.84" spread="9.700"/>
                    <measurement group_id="O3" value="-19.16" spread="10.708"/>
                    <measurement group_id="O4" value="-21.29" spread="10.135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 12 Percent Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.22" spread="8.967"/>
                    <measurement group_id="O2" value="-13.36" spread="8.949"/>
                    <measurement group_id="O3" value="-19.45" spread="11.072"/>
                    <measurement group_id="O4" value="-21.22" spread="11.368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 15 Percent Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.28" spread="10.739"/>
                    <measurement group_id="O2" value="-13.73" spread="8.485"/>
                    <measurement group_id="O3" value="-19.33" spread="10.884"/>
                    <measurement group_id="O4" value="-21.19" spread="10.675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 19 Percent Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.87" spread="9.554"/>
                    <measurement group_id="O2" value="-14.08" spread="8.822"/>
                    <measurement group_id="O3" value="-18.29" spread="9.707"/>
                    <measurement group_id="O4" value="-19.10" spread="9.957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 22 Percent Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.74" spread="9.992"/>
                    <measurement group_id="O2" value="-12.65" spread="9.591"/>
                    <measurement group_id="O3" value="-16.25" spread="11.292"/>
                    <measurement group_id="O4" value="-18.65" spread="10.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 26 Percent Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.54" spread="9.386"/>
                    <measurement group_id="O2" value="-11.83" spread="8.025"/>
                    <measurement group_id="O3" value="-15.18" spread="11.988"/>
                    <measurement group_id="O4" value="-18.28" spread="10.271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 29 Percent Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.23" spread="8.586"/>
                    <measurement group_id="O2" value="-12.49" spread="8.770"/>
                    <measurement group_id="O3" value="-18.83" spread="11.951"/>
                    <measurement group_id="O4" value="-19.80" spread="9.503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 29/Exit Percent Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.68" spread="8.940"/>
                    <measurement group_id="O2" value="-13.85" spread="9.568"/>
                    <measurement group_id="O3" value="-19.28" spread="14.099"/>
                    <measurement group_id="O4" value="-21.06" spread="11.086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in S-K Levels From Maintenance Phase Baseline to Maintenance Phase Day 2 to Day 29/Exit.</title>
        <time_frame>Maintenance phase baseline to Maintenance Phase Study Day 29/Exit, inclusive.</time_frame>
        <population>Maintenance Phase Intent- to-Treat (MP-ITT) population: all randomized subjects who received at least 1 Maintenance Phase dose and had at least 1 observed S-K assessment on or after Study Day 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator (Maintenance Phase)</title>
            <description>Placebo to mimic doses of experimental drug once daily between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O2">
            <title>ZS 5 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 5 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O3">
            <title>ZS 10 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 10 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O4">
            <title>ZS 15 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 15 g, once daily, orally as a suspension between Day 8 to 29, inclusive.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in S-K Levels From Maintenance Phase Baseline to Maintenance Phase Day 2 to Day 29/Exit.</title>
          <population>Maintenance Phase Intent- to-Treat (MP-ITT) population: all randomized subjects who received at least 1 Maintenance Phase dose and had at least 1 observed S-K assessment on or after Study Day 8.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MP Baseline S-K level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.55" spread="0.427"/>
                    <measurement group_id="O2" value="4.51" spread="0.357"/>
                    <measurement group_id="O3" value="4.38" spread="0.407"/>
                    <measurement group_id="O4" value="4.45" spread="0.372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 2 Mean change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.411"/>
                    <measurement group_id="O2" value="-0.01" spread="0.372"/>
                    <measurement group_id="O3" value="-0.04" spread="0.384"/>
                    <measurement group_id="O4" value="-0.02" spread="0.400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 8 Mean change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.538"/>
                    <measurement group_id="O2" value="0.30" spread="0.467"/>
                    <measurement group_id="O3" value="0.12" spread="0.523"/>
                    <measurement group_id="O4" value="-0.10" spread="0.535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 12 Mean change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.580"/>
                    <measurement group_id="O2" value="0.26" spread="0.541"/>
                    <measurement group_id="O3" value="0.10" spread="0.594"/>
                    <measurement group_id="O4" value="-0.11" spread="0.572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 15 Mean change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.694"/>
                    <measurement group_id="O2" value="0.25" spread="0.535"/>
                    <measurement group_id="O3" value="0.11" spread="0.552"/>
                    <measurement group_id="O4" value="-0.10" spread="0.546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 19 Mean change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="0.672"/>
                    <measurement group_id="O2" value="0.22" spread="0.580"/>
                    <measurement group_id="O3" value="0.17" spread="0.483"/>
                    <measurement group_id="O4" value="0.01" spread="0.605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 22 Mean change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="0.627"/>
                    <measurement group_id="O2" value="0.30" spread="0.563"/>
                    <measurement group_id="O3" value="0.27" spread="0.650"/>
                    <measurement group_id="O4" value="0.03" spread="0.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 26 Mean change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="0.623"/>
                    <measurement group_id="O2" value="0.34" spread="0.565"/>
                    <measurement group_id="O3" value="0.33" spread="0.673"/>
                    <measurement group_id="O4" value="0.05" spread="0.594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 29 Mean change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="0.545"/>
                    <measurement group_id="O2" value="0.28" spread="0.664"/>
                    <measurement group_id="O3" value="0.14" spread="0.668"/>
                    <measurement group_id="O4" value="-0.04" spread="0.554"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 29/Exit Mean change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.582"/>
                    <measurement group_id="O2" value="0.25" spread="0.645"/>
                    <measurement group_id="O3" value="0.11" spread="0.768"/>
                    <measurement group_id="O4" value="-0.09" spread="0.598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change in S-K Levels From Maintenance Phase Baseline to Maintenance Phase Day 2 to Day 29/Exit.</title>
        <time_frame>Maintenance phase baseline to Maintenance Phase Study Day 29/Exit, inclusive.</time_frame>
        <population>Maintenance Phase Intent- to-Treat (MP-ITT) population: all randomized subjects who received at least 1 Maintenance Phase dose and had at least 1 observed S-K assessment on or after Study Day 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator (Maintenance Phase)</title>
            <description>Placebo to mimic doses of experimental drug once daily between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O2">
            <title>ZS 5 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 5 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O3">
            <title>ZS 10 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 10 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O4">
            <title>ZS 15 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 15 g, once daily, orally as a suspension between Day 8 to 29, inclusive.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in S-K Levels From Maintenance Phase Baseline to Maintenance Phase Day 2 to Day 29/Exit.</title>
          <population>Maintenance Phase Intent- to-Treat (MP-ITT) population: all randomized subjects who received at least 1 Maintenance Phase dose and had at least 1 observed S-K assessment on or after Study Day 8.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MP Study Day 2 Percent change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39" spread="9.044"/>
                    <measurement group_id="O2" value="0.06" spread="8.036"/>
                    <measurement group_id="O3" value="-0.51" spread="8.862"/>
                    <measurement group_id="O4" value="-0.20" spread="8.984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 8 Percent change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.64" spread="12.291"/>
                    <measurement group_id="O2" value="6.93" spread="10.486"/>
                    <measurement group_id="O3" value="3.05" spread="12.346"/>
                    <measurement group_id="O4" value="-1.74" spread="12.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 12 Percent change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.70" spread="13.072"/>
                    <measurement group_id="O2" value="6.38" spread="12.287"/>
                    <measurement group_id="O3" value="2.85" spread="13.595"/>
                    <measurement group_id="O4" value="-2.00" spread="12.836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 15 Percent change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.51" spread="15.693"/>
                    <measurement group_id="O2" value="5.95" spread="12.169"/>
                    <measurement group_id="O3" value="2.93" spread="12.662"/>
                    <measurement group_id="O4" value="-1.89" spread="12.118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 19 Percent change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.96" spread="15.791"/>
                    <measurement group_id="O2" value="5.33" spread="12.934"/>
                    <measurement group_id="O3" value="4.28" spread="11.231"/>
                    <measurement group_id="O4" value=".095" spread="13.697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 22 Percent change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.84" spread="14.342"/>
                    <measurement group_id="O2" value="6.98" spread="12.774"/>
                    <measurement group_id="O3" value="6.79" spread="15.174"/>
                    <measurement group_id="O4" value="1.39" spread="12.782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 26 Percent change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.03" spread="14.566"/>
                    <measurement group_id="O2" value="7.98" spread="12.932"/>
                    <measurement group_id="O3" value="8.08" spread="15.516"/>
                    <measurement group_id="O4" value="1.88" spread="16.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 29 Percent change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.09" spread="13.116"/>
                    <measurement group_id="O2" value="6.12" spread="14.424"/>
                    <measurement group_id="O3" value="3.02" spread="17.785"/>
                    <measurement group_id="O4" value="-1.43" spread="13.664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 29/Exit Percent change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.97" spread="13.116"/>
                    <measurement group_id="O2" value="6.12" spread="14.424"/>
                    <measurement group_id="O3" value="3.02" spread="17.785"/>
                    <measurement group_id="O4" value="-1.43" spread="13.664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Hyperkalemia (S-K ≥ 5.1mmol/L)</title>
        <time_frame>Maintenance Phase baseline to maintenance Phase Study Day 29/Exit.</time_frame>
        <population>Maintenance Phase Intent- to-Treat (MP-ITT) population: all randomized subjects who received at least 1 Maintenance Phase dose and had at least 1 observed S-K assessment on or after Study Day 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator (Maintenance Phase)</title>
            <description>Placebo to mimic doses of experimental drug once daily between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O2">
            <title>ZS 5 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 5 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O3">
            <title>ZS 10 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 10 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O4">
            <title>ZS 15 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 15 g, once daily, orally as a suspension between Day 8 to 29, inclusive.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Hyperkalemia (S-K ≥ 5.1mmol/L)</title>
          <population>Maintenance Phase Intent- to-Treat (MP-ITT) population: all randomized subjects who received at least 1 Maintenance Phase dose and had at least 1 observed S-K assessment on or after Study Day 8.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="6" upper_limit="7"/>
                    <measurement group_id="O2" value="14" lower_limit="7" upper_limit="28"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">The Median time was not reached in the ZS 10 g group because fewer than 50% of patients in the group had a hyperkalemic event before the end of the Maintenance Phase.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">The Median time was not reached in the ZS 15 g group because fewer than 50% of patients in the group had a hyperkalemic event before the end of the Maintenance Phase.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean S-K Intra-subject Standard Deviation Calculated Among Subjects With ≥ 2 Values on or After Maintenance Phase Study Day 8</title>
        <time_frame>22 days; Maintenance Phase Day 8 - 29</time_frame>
        <population>Maintenance Phase Intent- to-Treat (ITT) population: all randomized subjects who received at least 1 Maintenance Phase dose and had at least 1 observed S-K assessment on or after Day 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator (Maintenance Phase)</title>
            <description>Placebo to mimic doses of experimental drug once daily between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O2">
            <title>ZS 5 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 5 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O3">
            <title>ZS 10 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 10 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O4">
            <title>ZS 15 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 15 g, once daily, orally as a suspension between Day 8 to 29, inclusive.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean S-K Intra-subject Standard Deviation Calculated Among Subjects With ≥ 2 Values on or After Maintenance Phase Study Day 8</title>
          <population>Maintenance Phase Intent- to-Treat (ITT) population: all randomized subjects who received at least 1 Maintenance Phase dose and had at least 1 observed S-K assessment on or after Day 8.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06392" lower_limit="0.05804" upper_limit="0.06980"/>
                    <measurement group_id="O2" value="0.06367" lower_limit="0.05574" upper_limit="0.07159"/>
                    <measurement group_id="O3" value="0.07708" lower_limit="0.06941" upper_limit="0.08474"/>
                    <measurement group_id="O4" value="0.06849" lower_limit="0.06126" upper_limit="0.07571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Who Remained Normokalemic During Maintenance Phase</title>
        <time_frame>Maintenance Phase Study Days 1, 2, 5, 8, 12, 15, 19, 22, 26, 29, and 35, inclusive.</time_frame>
        <population>Maintenance Phase Intent- to-Treat (MP-ITT) population: all randomized subjects who received at least 1 Maintenance Phase dose and had at least 1 observed S-K assessment on or after Study Day 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator (Maintenance Phase)</title>
            <description>Placebo to mimic doses of experimental drug once daily between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O2">
            <title>ZS 5 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 5 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O3">
            <title>ZS 10 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 10 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O4">
            <title>ZS 15 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 15 g, once daily, orally as a suspension between Day 8 to 29, inclusive.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Who Remained Normokalemic During Maintenance Phase</title>
          <population>Maintenance Phase Intent- to-Treat (MP-ITT) population: all randomized subjects who received at least 1 Maintenance Phase dose and had at least 1 observed S-K assessment on or after Study Day 8.</population>
          <units>Proportion of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.866"/>
                    <measurement group_id="O2" value="0.933"/>
                    <measurement group_id="O3" value="0.920"/>
                    <measurement group_id="O4" value="0.926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84"/>
                    <measurement group_id="O2" value="0.933"/>
                    <measurement group_id="O3" value="0.918"/>
                    <measurement group_id="O4" value="0.944"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.481"/>
                    <measurement group_id="O2" value="0.711"/>
                    <measurement group_id="O3" value="0.820"/>
                    <measurement group_id="O4" value="0.852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.400"/>
                    <measurement group_id="O2" value="0.750"/>
                    <measurement group_id="O3" value="0.787"/>
                    <measurement group_id="O4" value="0.849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.438"/>
                    <measurement group_id="O2" value="0.705"/>
                    <measurement group_id="O3" value="0.851"/>
                    <measurement group_id="O4" value="0.827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.449"/>
                    <measurement group_id="O2" value="0.744"/>
                    <measurement group_id="O3" value="0.787"/>
                    <measurement group_id="O4" value="0.882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.442"/>
                    <measurement group_id="O2" value="0.674"/>
                    <measurement group_id="O3" value="0.667"/>
                    <measurement group_id="O4" value="0.882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.486"/>
                    <measurement group_id="O2" value="0.738"/>
                    <measurement group_id="O3" value="0.711"/>
                    <measurement group_id="O4" value="0.843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.507"/>
                    <measurement group_id="O2" value="0.667"/>
                    <measurement group_id="O3" value="0.816"/>
                    <measurement group_id="O4" value="0.907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MP Study Day 29/Exit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.476"/>
                    <measurement group_id="O2" value="0.711"/>
                    <measurement group_id="O3" value="0.760"/>
                    <measurement group_id="O4" value="0.852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Relapse in S-K Values</title>
        <description>Median time to relapse in S-K values (return to original Acute Phase S-K baseline value)</description>
        <time_frame>Maintenance phase Study Day 1 to Study Day 29/Exit.</time_frame>
        <population>Maintenance Phase Intent- to-Treat (MP-ITT) population: all randomized subjects who received at least 1 Maintenance Phase dose and had at least 1 observed S-K assessment on or after Study Day 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator (Maintenance Phase)</title>
            <description>Placebo to mimic doses of experimental drug once daily between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O2">
            <title>ZS 5 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 5 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O3">
            <title>ZS 10 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 10 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
          </group>
          <group group_id="O4">
            <title>ZS 15 g Once Daily (Maintenance Phase)</title>
            <description>Sodium zirconium cyclosilicate (ZS) 15 g, once daily, orally as a suspension between Day 8 to 29, inclusive.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Relapse in S-K Values</title>
          <description>Median time to relapse in S-K values (return to original Acute Phase S-K baseline value)</description>
          <population>Maintenance Phase Intent- to-Treat (MP-ITT) population: all randomized subjects who received at least 1 Maintenance Phase dose and had at least 1 observed S-K assessment on or after Study Day 8.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="12" upper_limit="28"/>
                    <measurement group_id="O2" value="29" lower_limit="29" upper_limit="NA">The confidence interval for the median is based on when the lower and upper limits of the confidence interval for survival function reach 50%. However, the upper limit for survival function in the ZS 5 g QD did not reach 50% in the Maintenance Phase.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Fewer than 50% of patients in the ZS 10 g QD had relapsed at the end of the Maintenance Phase. Therefore, median was not reached.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Fewer than 50% of patients in the ZS 15 g QD had relapsed at the end of the Maintenance Phase. Therefore, median was not reached.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exponential Rate of Change in S-K Values During the Acute Phase at 24 Hours and 48 Hours of Study Drug Treatment.</title>
        <time_frame>Acute Phase 24 hours and Acute Phase 48 hours.</time_frame>
        <population>Acute Phase ITT Population included all subjects who received at least 1 Acute Phase dose and had any post-baseline S-K levels after receiving the investigational product during the first 48 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Phase: ZS 10 g TID</title>
            <description>ZS (sodium zirconium cyclosilicate) 10 g, three times a day, orally as suspension in water for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Exponential Rate of Change in S-K Values During the Acute Phase at 24 Hours and 48 Hours of Study Drug Treatment.</title>
          <population>Acute Phase ITT Population included all subjects who received at least 1 Acute Phase dose and had any post-baseline S-K levels after receiving the investigational product during the first 48 hours.</population>
          <units>log(mmol/L/hour)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hours after start of ZS dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00373" spread="0.000231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours of start of ZS dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00324" spread="0.000130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in S-K Values (Blood) at All Measured Time Intervals Post Dose Acute Phase.</title>
        <time_frame>All measured time intervals post dose during the Acute Phase.</time_frame>
        <population>Acute Phase ITT Population included all subjects who received at least 1 Acute Phase dose and had any post-baseline S-K levels after receiving the investigational product during the first 48 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Phase: ZS 10 g TID</title>
            <description>ZS (sodium zirconium cyclosilicate) 10 g, three times a day, orally as suspension in water for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in S-K Values (Blood) at All Measured Time Intervals Post Dose Acute Phase.</title>
          <population>Acute Phase ITT Population included all subjects who received at least 1 Acute Phase dose and had any post-baseline S-K levels after receiving the investigational product during the first 48 hours.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Acute phase baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.55" spread="0.449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour after start of ZS dosing Mean change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours after start of ZS dosing Mean change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours after start of ZS dosing Mean change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours after start of ZS dosing Mean change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour after 1st dose Study Day 2 Mean change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours after start of ZS dosing Mean change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.05" spread="0.510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline in S-K Values (Blood) at All Measured Time Intervals Post Dose Acute Phase.</title>
        <time_frame>All measured time intervals post dose during the Acute Phase.</time_frame>
        <population>Acute Phase ITT Population included all subjects who received at least 1 Acute Phase dose and had any post-baseline S-K levels after receiving the investigational product during the first 48 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Phase: ZS 10 g TID</title>
            <description>ZS (sodium zirconium cyclosilicate) 10 g, three times a day, orally as suspension in water for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in S-K Values (Blood) at All Measured Time Intervals Post Dose Acute Phase.</title>
          <population>Acute Phase ITT Population included all subjects who received at least 1 Acute Phase dose and had any post-baseline S-K levels after receiving the investigational product during the first 48 hours.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour after start of ZS dosing Percent change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.91" spread="7.741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours after start of ZS dosing Percent change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.13" spread="7.706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours after start of ZS dosing Percent change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.00" spread="7.123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours after start of ZS dosing Percent change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.03" spread="7.808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour after 1st dose Study Day 2 Percent change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.41" spread="7.720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours after start of ZS dosing Percent change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.56" spread="8.506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Who Achieve Normokalemia During the Acute Phase at 24 and 48 Hours After Start of Dosing</title>
        <time_frame>Through 48 hours acute phase</time_frame>
        <population>Acute Phase ITT Population included all subjects who received at least 1 Acute Phase dose and had any post-baseline S-K levels after receiving the investigational product during the first 48 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Phase: ZS 10 g TID</title>
            <description>ZS (sodium zirconium cyclosilicate) 10 g, three times a day, orally as suspension in water for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Who Achieve Normokalemia During the Acute Phase at 24 and 48 Hours After Start of Dosing</title>
          <population>Acute Phase ITT Population included all subjects who received at least 1 Acute Phase dose and had any post-baseline S-K levels after receiving the investigational product during the first 48 hours.</population>
          <units>Proportion of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hours after start of dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours after of start dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Normalization (3.50-5.0 mmol/L) in S-K Levels in the 48 Hours of Initial Treatment</title>
        <time_frame>Through 48 hours acute phase</time_frame>
        <population>Acute Phase ITT Population included all subjects who received at least 1 Acute Phase dose and had any post-baseline S-K levels after receiving the investigational product during the first 48 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Phase: ZS 10 g TID</title>
            <description>ZS (sodium zirconium cyclosilicate) 10 g, three times a day, orally as a suspension for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Normalization (3.50-5.0 mmol/L) in S-K Levels in the 48 Hours of Initial Treatment</title>
          <population>Acute Phase ITT Population included all subjects who received at least 1 Acute Phase dose and had any post-baseline S-K levels after receiving the investigational product during the first 48 hours.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" lower_limit="2" upper_limit="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events were collected beginning with the first administration of study drug and through end of study treatment follow up visit. End of treatment study follow up visit was 7 days +/- 1 day after last dose of investigational product.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ZS 10 g TID (Acute Phase)</title>
          <description>ZS (sodium zirconium cyclosilicate) 10 g, three times a day, orally as suspension in water for 48 hours.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Comparator (Maintenance Phase)</title>
          <description>Placebo to mimic doses of experimental drug once daily between Days 8 to 29, inclusive.</description>
        </group>
        <group group_id="E3">
          <title>ZS 5 g Once Daily (Maintenance Phase)</title>
          <description>Sodium zirconium cyclosilicate (ZS) 5 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
        </group>
        <group group_id="E4">
          <title>ZS 10 g Once Daily (Maintenance Phase)</title>
          <description>Sodium zirconium cyclosilicate (ZS) 10 g, once daily, orally as a suspension between Days 8 to 29, inclusive.</description>
        </group>
        <group group_id="E5">
          <title>ZS 15 g Once Daily (Maintenance Phase)</title>
          <description>Sodium zirconium cyclosilicate (ZS) 15 g, once daily, orally as a suspension between Day 8 to 29, inclusive.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <description>Including generalized and peripheral edema</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Generalised Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dysponea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>ZS Pharma has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>AstraZeneca Clinical Study Information Center</name_or_title>
      <organization>ZS Pharma, Inc.</organization>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

